Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1

NCT06744504 | Recruiting Phase 3

• 1 other identifier: IIT2024094
• Study Type: interventional
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Leukemia is one of the common malignant tumors that threaten human health. Although the efficacy of AML treatment has improved significantly in recent years, it remains one of the major diseases threatening human health. Current research on AML treatment mainly has two directions. One is the addition of new targeted therapy drugs, and the other research direction is to enhance the intensity of AML chemotherapy, including the use of large doses of anthracycline drugs or the use of high-dose cytarabine treatment. Since the 1990s, induction remission has been achieved by using anthracyclines in combination with high-dose cytarabine. The ECOG (Eastern Cooperative Oncology Group) contends that high-dose induction chemotherapy fails to enhance the bone marrow remission rate but elevates the chemotherapy-related mortality rate. Bradstock and the Australian Group also noted that although it does not increase the bone marrow remission rate, it can result in longer survival time and disease-free survival time. The clinical study from EORTC-GIMEMA AML-12 discovered that AML patients under the age of 45 could benefit from induction therapy incorporating high-dose cytarabine. In our previous randomized controlled clinical trials, it was found that the HAD and DA regimens containing intermediate-dose cytarabine could enhance the complete remission rate and improve the overall survival of adult AML. However, the degree of benefit varies among different AML subgroups. The abnormalities of RUNX1-RUNX1T1 and CBFβ-MYH11 respectively involve a subunit of CBF (core binding factor), thus the two are collectively called CBF leukemia. Previous retrospective studies show that this type of leukemia benefits from intensified treatment regimens such as FLAG. However, at present, there is a lack of prospective randomized controlled clinical studies to confirm this. Therefore, in this study, we intend to further verify through a prospective randomized controlled clinical trial whether the induction treatment regimen containing intermediate-dose cytarabine can improve the long-term efficacy of adult RUNX1-RUNX1T1 acute myeloid leukemia.

Conditions

AML; RUNX1-RUNX1T1 Fusion Protein Expression

Outcome Measures

Primary Outcomes (1)

• overall survival

  Used to evaluate all patients who enter clinical trials. From the date of entry into the trial until the date of patient death (including any cause) or last survival follow-up.

  up to 2 years after the date of the last enrolled participants

Secondary Outcomes (8)

• Complete remission (CR)/CR with partial hematologic recovery (CRh)/CR with incomplete hematologic recovery (CRi) rate after induction therapy

  up to 3 months after the date of the last enrolled participants

• RUNX1::RUNX1T1 minimal residual disease (MRD) reduction >3 logs after 2 courses

  up to 2 years after the date of the last enrolled participants

• RUNX1::RUNX1T1 molecular MRD undectable rate

  up to 2 years after the date of the last enrolled participants

• Relapse-free survival (RFS)

  up to 2 years after the date of the last enrolled participants

• Event-free survival (EFS)

  up to 2 years after the date of the last enrolled participants

Study Arms (2)

standard-dose Cytarabine

ACTIVE COMPARATOR

Induction therapy: Cytarabine (Ara-c) 100mg/ m2/ day, day 1-7; Daunorubicin (DNR) 60mg/m2/ day, day 1-3; Those who did not meet CR were treated with IAC regimen. IAC: IDA 8 mg/m2/d, D1-3; Ara-c 100 mg/m2, D1-7; CTX 350mg/m2, D2,5; Post-remission treatment options: High dose Ara-C(HDAC) : 3 cycles Ara-C 3g/㎡/q12h, days 1, 3 and 5 For patietns RUNX1-RUNX1 MRD reduction \< 3 logs after 2 courses, allo-transplantation is recommended if donor is available.

Drug: cytarabine; Drug: daunorubicin; Drug: idarubicin; Drug: cyclophosphamide

Intermediate-dose Cytarabine

EXPERIMENTAL

Induction therapy: Cytarabine (Ara-c) 100mg/ m2/ day, day 1-4; 1g/㎡/q12h, day 5-7; Daunorubicin (DNR) 60mg/m2/ day, day 1-3; Those who did not meet CR were treated with IAC regimen. IAC: IDA 8 mg/m2/d, D1-3; Ara-c 100 mg/m2, D1-7; CTX 350mg/m2, D2,5; Post-remission treatment options: High dose Ara-C(HDAC) : 3 cycles; Ara-C 3g/㎡/q12h, days 1, 3 and 5. For patietns RUNX1-RUNX1 MRD reduction \< 3 logs after 2 courses, allo-transplantation is recommended if donor is available.

Drug: cytarabine; Drug: daunorubicin; Drug: idarubicin; Drug: cyclophosphamide

Interventions

cytarabine DRUG

Cytarabine combined with daunorubicin was used for induction therapy. According to the different doses of cytarabine, it was divided into standard dose group and intermediate dose group.In addition, high doses of cytarabine are also used for post-remission treatment.

Intermediate-dose Cytarabine; standard-dose Cytarabine

daunorubicin DRUG

combined with cytarabine and used for induction therapy

Intermediate-dose Cytarabine; standard-dose Cytarabine

idarubicin DRUG

combined with cytarabine and cyclophosphamide and used for post-remission treatment

Intermediate-dose Cytarabine; standard-dose Cytarabine

cyclophosphamide DRUG

combined with cytarabine and idarubicin and used for post-remission treatment

Intermediate-dose Cytarabine; standard-dose Cytarabine

Eligibility Criteria

• Age: 14 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• AML conforming to WHO (2022) or ICC standards
• Possessing the RUNX1::RUNX1T1 fusion gene
• Age ranging from 14 to 60 years old, regardless of gender.
• The performance status assessment of the Eastern Cooperative Oncology Group (ECOG-PS) being 0 - 2.
• Meeting the requirements of the following laboratory examination indicators (conducted within 7 days before treatment):
• \) Total bilirubin ≤ 1.5 times the upper limit of the normal value for the same age group; 2) AST and ALT ≤ 2.5 times the upper limit of the normal value for the same age group; 3) Serum creatinine \< 2 times the upper limit of the normal value for the same age group; 4) Cardiac enzymes \< 2 times the upper limit of the normal value for the same age group; 5) The cardiac ejection fraction determined by echocardiography (ECHO) \> 50%. An informed consent form must be signed before the commencement of all specific research procedures, either by the patient themselves or their immediate relatives. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the disease, the informed consent form shall be signed by the legal guardian or the immediate relatives of the patient.

You may not qualify if:

• Acute promyelocytic leukemia accompanied by PML-RARA fusion gene.
• Acute myeloid leukemia featuring BCR-ABL fusion gene.
• Patients undergoing retreatment (but can receive cytoreductive therapy with hydroxyurea and cytarabine).
• Individuals concurrently having malignant tumors in other organs (requiring treatment).
• Active cardiac disorders, defined as one or more of the following:
• \) A history of uncontrolled or symptomatic angina pectoris; 2) Myocardial infarction less than 6 months from study enrollment; 3) A history of significant arrhythmia requiring medication or presenting with severe clinical symptoms; 4) Uncontrolled or symptomatic congestive heart failure (\> NYHA Class 2)
• \. Severe infectious diseases (untreated tuberculosis, pulmonary aspergillosis).
• \. Individuals deemed ineligible for enrollment by the investigator.

Sponsors & Collaborators

• Institute of Hematology & Blood Diseases Hospital, China: lead

Study Sites (1)

Blood Diseases Hospital

Tianjin, Tianjin Municipality, 300020, China

RECRUITING

MeSH Terms

Interventions

Cytarabine; Daunorubicin; Idarubicin; Cyclophosphamide

Intervention Hierarchy (Ancestors)

Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Arabinonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Anthracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Aminoglycosides; Glycosides; Carbohydrates; Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Phosphoramides; Organophosphorus Compounds

Central Study Contacts

Hui Wei, MD

CONTACT

13132507161; weihui@ihcams.ac.cn

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 17, 2024
• First Posted: December 20, 2024
• Study Start: January 10, 2025
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2029
• Last Updated: March 27, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)